Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA grants approval for Copiktra for CLL/SLL, accelerated approval in follicular lymphoma

Sep. 25, 2018

Phase IIa trial of EPI-589 in ALS shows improvement in CSF and plasma-based biomarkers

Sep. 25, 2018

Imfinzi approved in E.U. for locally advanced, unresectable NSCLC

Sep. 25, 2018

FDA lifts partial clinical hold on tazemetostat trials

Sep. 25, 2018

New PKU mouse model developed

Sep. 25, 2018

AnaptysBio reports promising topline proof-of-concept data on etokimab in severe eosinophilic asthma

Sep. 25, 2018

Ovid initiates phase II studies of OV-935 for rare epilepsies

Sep. 25, 2018

FDA lifts clinical hold for Sarepta's DMD micro-dystrophin gene therapy program

Sep. 25, 2018

PhaseBio reports promising phase I results with ticagrelor reversal agent PB-2452

Sep. 25, 2018

Xospata approved in Japan for FLT3 mutation-positive relapsed or refractory AML

Sep. 25, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...